Oncimmune receives regulatory approval from Israel for lung cancer diagnosis kit

Lung cancer kills more people in Israel than any other form of the disease, said the company.

Smokers at risk can by identified by Oncimmune

Oncimmune Holdings PLC (LON:ONC) has received regulatory approval to sell its early stage lung cancer detector, EarlyCDT-Lung, in Israel.

Lung cancer kills more people in Israel than any other form of the disease, said the company.

On an age-standardised basis, Israel's lung cancer mortality rate is 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region. 

Adam Hill, chief executive, added that the approval 'paves the way for the near-term commencement of commercial sales of EarlyCDT-Lung in the sophisticated healthcare market of Israel'. 

Oncimmune already has exclusive distribution agreements in numerous countries including Germany, France, Italy and Spain, while approval for an EarlyCDT-Lung kit was recently granted in Singapore.

Quick facts: Oncimmune

Price: 133.5 GBX

Market: AIM
Market Cap: £84.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...



Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

17 hours, 3 minutes ago

2 min read